TCGA-86-8674-01A-21R-2403-07
— · cohortA2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA2
- subtype
- cohortA2
- age_years
- 50
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.460
- PANCREAS_BETA_CELLS+0.440
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.440
- FATTY_ACID_METABOLISM+0.380
- ADIPOGENESIS+0.320
- PEROXISOME+0.300
- WNT_BETA_CATENIN_SIGNALING+0.290
- UNFOLDED_PROTEIN_RESPONSE+0.260
- XENOBIOTIC_METABOLISM+0.260
- UV_RESPONSE_UP+0.230
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.460
- E2F_TARGETS-0.460
- G2M_CHECKPOINT-0.450
- INTERFERON_GAMMA_RESPONSE-0.400
- INTERFERON_ALPHA_RESPONSE-0.380
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.360
- INFLAMMATORY_RESPONSE-0.350
- MITOTIC_SPINDLE-0.340
- KRAS_SIGNALING_UP-0.300
- IL6_JAK_STAT3_SIGNALING-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | X265fd2ee.a8d9.4142.bf96.86a40f37234e | — | cohortA2 | 0.836 |
| 2 | TCGA-UF-A7JF-01A-11R-A34R-07 | — | — | 0.808 |
| 3 | TCGA-49-4486-01A-01R-1206-07 | — | cohortA2 | 0.799 |
| 4 | TCGA-D8-A1JS-01A-11R-A13Q-07 | — | B | 0.796 |
| 5 | TCGA-BA-6869-01A-11R-1873-07 | — | — | 0.795 |
| 6 | MNG124 | — | — | 0.788 |
| 7 | TCGA-69-8253-01A-11R-2287-07 | — | cohortA2 | 0.788 |
| 8 | SRR8943041 | — | — | 0.786 |
| 9 | SRR8943024 | — | — | 0.785 |
| 10 | SRR4296082 | — | cohortA1 | 0.779 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.460 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.440 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.440 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.380 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.320 | Inavolisib | — uncovered |
| PEROXISOME | 0.300 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.290 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.260 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.260 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.230 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.210 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.170 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.130 | Idelalisib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| GLYCOLYSIS | 0.090 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.080 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.080 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.070 | Idelalisib | — uncovered |